1141669-61-5Relevant articles and documents
Lipase Catalyzed Regioselective Lactamization as a Key Step in the Synthesis of N-Boc (2R)-1,4-Oxazepane-2-Carboxylic Acid
Aurell, Carl-Johan,Karlsson, Staffan,Pontén, Fritiof,Andersen, S?ren M.
, p. 1116 - 1119 (2014)
A synthesis of N-Boc (2R)-1,4-oxazepane-2-carboxylic acid 1 has been developed in 39% yield over seven steps starting from methyl (2R)-glycidate 2. The key step was a lipase-catalyzed regioselective lactamization of amino diester 5 into seven-membered lactam 6. The transformation was performed using SpinChem rotating flow cell technology which simplified the work up and the recycling of the enzyme. Subsequent N-Boc protection followed by chemoselective borane reduction of the lactam moiety afforded 4-tert-butyl 2-methyl (2R)-1,4-oxazepane-2,4-dicarboxylate 8. Finally, hydrolysis mediated by LiBr/Et3N in wet acetonitrile yielded the title compound (2R)-4-(tert-butoxycarbonyl)-1,4-oxazepane-2-carboxylic acid 1.
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
-
, (2017/01/05)
The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
-
, (2015/08/04)
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
